GSK Explores Potential Link Between Shingles Vaccine and Dementia Risk Reduction

In a groundbreaking development, pharmaceutical giant GSK is investigating whether its highly successful shingles vaccine may also play a significant role in reducing the risk of dementia. This initiative could not only bolster the vaccine’s appeal but also provide new insights into the prevention of neurodegenerative diseases as the global population ages.

Continue reading